BSX · Boston Scientific Corp

Acquistion made pursuant to an election by the reporting person to rebalance their holdings under the Company's 401(k) Retirement Savings Plan, which resulted in a discretionary transaction in shares of the Company's common stock.

Acquistion made pursuant to an election by the reporting person to rebalance their holdings under the Company's 401(k) Retirement Savings Plan, which resulted in a discretionary transaction in shares of the Company's common stock.

Represents the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $47.21 to $47.98, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

Represents the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $48.54 to $48.60, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

Represents the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $47.87 to $48.47, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

Represents the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $48.055 to $48.070, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

Acquistion made pursuant to an election by the reporting person to rebalance their holdings under the Company's 401(k) Retirement Savings Plan, which resulted in a discretionary transaction in shares of the Company's common stock.

Acquistion made pursuant to an election by the reporting person to rebalance their holdings under the Company's 401(k) Retirement Savings Plan, which resulted in a discretionary transaction in shares of the Company's common stock.

Balance reflects the most current data available with regard to share holdings in the Company's 401(k) Retirement Savings Plan.

Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

Shares of common stock will be issued to the reporting person in four equal annual installments beginning on July 1, 2026, the first anniversary of the date of grant.

This transaction involved a gift of securities by the reporting person to The Michael F. Mahoney Term Irrevocable Trust - 2026, which is administered by an independent trustee.

Represents the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $56.49 to $56.5009, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

Represents the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $55.85 to $56.00, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

Represents the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $56.93 to $56.96, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

Deferred stock units were granted in lieu of 50% yearly cash compensation and vest in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Directors service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. Reflects a value of $72,500 (representing 50% of the amount of the non-employee director compensation program's cash retainer having a value of $125,000 and committee chair retainer having a value of $20,000) divided by the closing price of the common stock on the date of grant.

Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

Annual equity award in the form of deferred stock units vesting in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Director service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. Reflects a value of $150,500 (representing 70% of the non-employee director compensation program's annual equity award having a value of $215,000) divided by the closing price of common stock on the date of grant.

Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

Reflects a value of $215,000 divided by the closing price of common stock on the date of grant.

Annual equity award in the form of deferred stock units vesting in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Director service in accordance with the Company's Non-Employee Director Deferred Compensation Plan.

Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

Reflects a value of $215,000 divided by the closing price of common stock on the date of grant.

Annual equity award in the form of deferred stock units vesting in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Director service in accordance with the Company's Non-Employee Director Deferred Compensation Plan.

Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $215,000 divided by the closing price of common stock on the date of grant.

Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $215,000 divided by the closing price of common stock on the date of grant.

Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $215,000 divided by the closing price of common stock on the date of grant.

Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

Deferred stock units were granted in lieu of 100% yearly cash compensation and vest in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Directors service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. Reflects a value of $125,000 (representing 100% of the amount of the non-employee director compensation program's cash retainer) divided by the closing price of the common stock on the date of grant.

Grant of restricted stock in lieu of 50% yearly cash compensation, vesting in full upon the next annual meeting of stockholders. Reflects a value of approximately $72,500 (representing 50% of the amount of the non-employee director compensation program's cash retainer having a value of $125,000 and committee chair retainer having a value of $20,000) divided by the closing price of the common stock on the date of grant.

Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $215,000 divided by the closing price of common stock on the date of grant.

Grant of restricted stock in lieu of 80% yearly cash compensation, vesting in full upon the next annual meeting of stockholders. Reflects a value of approximately $100,000 (representing 80% of the amount of the non-employee director compensation program's cash retainer having a value of $125,000) divided by the closing price of the common stock on the date of grant.

Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $215,000 divided by the closing price of common stock on the date of grant.

Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $215,000 divided by the closing price of common stock on the date of grant. Reflects a value of $64,500 (representing 30% of the amount of the non-employee director compensation program's annual equity award having a value of $215,000) divided by the closing price of common stock on the date of grant.

Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $215,000 divided by the closing price of common stock on the date of grant.

Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

Shares of common stock will be issued to the reporting person in four equal annual installments beginning on May 2, 2023, the first anniversary of the date of grant.

Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

Shares of common stock will be issued to the reporting person in four equal annual installments beginning on May 2, 2023, the first anniversary of the date of grant.

Restricted stock granted in lieu of 50% of cash compensation, vesting in full upon the next annual meeting of stockholders. Reflects a value of $1,845.25, divided by the closing price of common stock on the date of grant.

Grant of restricted stock in lieu of 100% yearly cash compensation, following initial appointment to the Board of Directors, which, pursuant to the Company's non-employee director compensation program, has been prorated for the time period from the effective date of the appointment to the date of the Company's 2026 annual meeting of stockholders. Reflects a value of approximately $24,662.50 (representing 100% of the prorated amount of the non-employee director compensation program's cash retainer having a value of $125,000) divided by the closing price of the common stock on the date of grant.

Grant of restricted stock to non-employee director following initial appointment to the Board of Directors, which, pursuant to the Company's non-employee director compensation program, has been prorated for the time period from the effective date of the appointment to the date of the Company's 2026 annual meeting of stockholders. The grant of restricted stock vests in full upon the next annual meeting of stockholders. Reflects a value of approximately $42,419.50 (representing 100% of the prorated amount of the non-employee director compensation program's annual equity award having a value of $215,000) divided by the closing price of common stock on the date of grant.

Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

Grant of deferred stock units in lieu of 100% yearly cash compensation following initial appointment to the Board of Directors, which, pursuant to the Company's non-employee director compensation program, has been prorated for the time period from the effective date of the appointment to the date of the Company's 2026 annual meeting of stockholders. The grant of deferred stock units vests in full upon the next annual meeting of stockholders. Reflects a value of approximately $24,662.50 (representing 100% of the prorated amount of the non-employee director compensation program's cash retainer having a value of $125,000) divided by the closing price of the common stock on the date of grant. Vested shares will be issued to the reporting person following the reporting person's separation from Board of Director service, in accordance with the Company's Non-Employee Director Deferred Compensation Plan.

Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

Deferred stock units granted in lieu of 50% yearly cash compensation, vesting in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Directors service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. Reflects a value of $1,845.25, divided by the closing price of the common stock on the date of grant.

Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

Grant of deferred stock units to non-employee director following initial appointment to the Board of Directors, which, pursuant to the Company's non-employee director compensation program, has been prorated for the time period from the effective date of the appointment to the date of the Company's 2026 annual meeting of stockholders. The grant of deferred stock units vests in full upon the next annual meeting of stockholders. Reflects a value of approximately $42,419.50 (representing 100% of the prorated amount of the non-employee director compensation program's annual equity award having a value of $215,000) divided by the closing price of the common stock on the date of grant. Vested shares will be issued to the reporting person following the reporting person's separation from Board of Director service, in accordance with the Company's Non-Employee Director Deferred Compensation Plan.

Grant of deferred stock units in lieu of 100% yearly cash compensation following initial appointment to the Board of Directors, which, pursuant to the Company's non-employee director compensation program, has been prorated for the time period from the effective date of the appointment to the date of the Company's 2026 annual meeting of stockholders. The grant of deferred stock units vests in full upon the next annual meeting of stockholders. Reflects a value of approximately $24,662.50 (representing 100% of the prorated amount of the non-employee director compensation program's cash retainer having a value of $125,000) divided by the closing price of the common stock on the date of grant. Vested shares will be issued to the reporting person following the reporting person's separation from Board of Director service, in accordance with the Company's Non-Employee Director Deferred Compensation Plan.

Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

Shares of common stock will be issued to the reporting person in four equal annual installments beginning on March 1, 2025, the first anniversary of the date of grant.

Acquistion made pursuant to an election by the reporting person to rebalance their holdings under the Company's 401(k) Retirement Savings Plan, which resulted in a discretionary transaction in shares of the Company's common stock.

Balance reflects the most current data available with regard to share holdings in the Company's 401(k) Retirement Savings Plan.

Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant.

Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant.